Enhance Skin Products (EHSK) 10-Q 6 Sep 16 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jul. 31, 2016	Sep. 01, 2016
Document And Entity Information
Entity Registrant Name	Enhance Skin Products Inc
Entity Central Index Key	1,395,400
Document Type	10-Q
Document Period End Date	Jul. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--04-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		115,889,205
Trading Symbol	EHSK
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2016	Apr. 30, 2016
ASSETS
Cash	$ 47,377	$ 2,847
Prepaid Expenses	13,423
Total current assets	60,800	2,847
Goodwill	1	1
Total assets	60,801	2,848
Liabilities
Accounts payable and accrued liabilities	271,475	271,635
Accounts payable to a related party (Note 4)	107,941	75,607
Accounts payable to related parties convertible into shares (Note 4)	318,880	248,600
Advances from a related party (Note 4)	96,489	96,489
Advances from a related party convertible into shares (Note 4)	316,575	305,540
Secured promissory note (Note 5)	100,000
Total current liabilities	1,211,360	997,871
Total liabilities	1,211,360	997,871
Stockholders' deficit
Authorized: 600,000,000 common shares par value $0.001 as of July 31, 2016 (April 30, 2016: 300,000,000 common shares) - (Note 6) Issued and outstanding 115,889,205 common shares as of July 31, 2015 (April 30, 2016: 113,951,705 common shares) - (Note 6)	115,889	113,951
Additional paid-in capital	1,991,963	1,971,548
Accumulated other comprehensive gain	9,032	8,809
Accumulated deficit	(3,267,443)	(3,089,331)
Total stockholders' deficit	(1,150,559)	(995,023)
Total liabilities and stockholders' deficit	$ 60,801	$ 2,848

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2016	Apr. 30, 2016
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	600,000,000	300,000,000
Common Stock, Shares Issued	115,889,205	113,951,705
Common Stock, Shares Outstanding	115,889,205	113,951,705

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2016	Jul. 31, 2015
Income Statement [Abstract]
SALES	$ 185	$ 155
EXPENSES
General and administrative	8,420	4,287
Legal and professional fees	166,347	17,298
Marketing
Total operating expenses	174,767	21,585
Exchange gain	(4,291)
Interest expense	7,821	7,143
Net loss for the period before income taxes	(178,112)	(28,573)
Income taxes
Net loss for the period	(178,112)	(28,573)
Foreign currency translation adjustment	223	(749)
Comprehensive loss	$ (177,889)	$ (29,322)
Loss per share, basic and diluted	$ (0.0015)	$ (0.0003)
Weighted average number of common shares outstanding	115,253,490	101,017,881

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2016	Jul. 31, 2015
OPERATING ACTIVITIES
Net loss for the period	$ (178,112)	$ (28,573)
Interest expense	7,821	7,143
Net change in non-cash working capital balances:
Shares issued against consulting expenses	14,532
Prepayments	(13,423)
Accounts payable to related party	32,334
Accounts payable to related parties convertible into shares	70,280
Accounts payable and accrued liabilities	(160)	(4,789)
Cash used in operating activities	(66,728)	(26,219)
FINANCING ACTIVITIES
Proceeds from issuance of secured promissory note	100,000	43,000
Advances from a related party	11,035	2,183
Cash provided by financing activities	111,035	45,183
Net increase in cash during the period	44,307	18,964
Effect of foreign currency translation	223	(749)
Cash, beginning of the period	2,847	1,582
Cash, end of period	47,377	19,797
Supplemental disclosure with respect to cash flows:
Cash paid for income taxes
Cash paid for interest

Basis of Presentation

Basis of Presentation	3 Months Ended
	Jul. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 1. BASIS OF PRESENTATION The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial positions, results of operations, and cash flows at July 31, 2016 and 2015, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these unaudited interim condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s April 30, 2016 and 2015 audited financial statements. The results of operations for the period ended July 31, 2016 and 2015 are not necessarily indicative of the operating results for the full year.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Jul. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS The management has evaluated all recent pronouncements issued by the FASB or other authoritative standards groups with their effective dates. The management believes that these are either not applicable or are not expected to be significant to the condensed consolidated financial statements of the Company.

Going Concern

Going Concern	3 Months Ended
	Jul. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As at July 31, 2016 the Company has a working capital deficit of $1,150,560 and accumulated deficit of $3,267,443. The Company has relied on advances from its former CEO, director, Mercuriali Ltd and a related party to meet the working capital requirements. On June 19, 2015, the Company issued a convertible promissory note in the amount of $43,000 to Vis Vires Group Inc. On December 28, 2015, Vis Vires Group Inc. issued a notice of conversion and elected to convert $12,000 of the principal amount at an applicable conversion price of $0.0017 per share of common stock. Resultantly, the Company issued 7,058,824 shares of common stock. The principal amount and interest in total of $33,500 was paid on March 23, 2016. On September 29, 2015, as amended January 22, 2016, Mercuriali Ltd agreed to advance the Company an additional $90,000. Effective March 21, 2016, the Company entered into a Loan Agreement (Amendment 5) with Mercuriali Ltd. and Samuel Asculai providing for an increase in the loan amounts by Mercuriali Ltd. and Samuel Asculai in the event no additional third party monies are received by the Company from US$90,000 to US$150,000. On July 7, 2016, the Company and Integumen Limited (formerly Biosurface Limited) (“Integumen”) entered into a non-binding term sheet in respect of a strategic collaboration and an option agreement (the “Option Agreement”). The Company also issued to Integumen a secured promissory note in the amount of $100,000 (the “Note”). Under the Note, Integumen agreed to loan the Company US$100,000 conditional upon the Company entering into the Option Agreement and entering into good faith negotiations with a view to entering into a strategic collaboration via an asset purchase agreement (the “APA”). As explained in Note 5, on July 7, 2016, the full balance will become due on the earlier of (i) the demand made by the Noteholder or on the 6 month anniversary date (ii) the completion of the Asset Purchase Agreement or (iii) when, upon the occurrence and during the continuance of an event of default. . In the event of non-payment, the company becomes due to pay 5% per annum of the outstanding principal from the Maturity date. The expiration of the Option Agreement has been extended to September 8, 2016. The Option Agreement grants Integumen an option to acquire substantially all of the Company’s assets under a plan of reorganization (the “Option”). The consideration payable upon exercise of the Option is a sum equal to £3,030,000 ($4,013,293) comprised of £2,760,000 ($3,655,620) in shares of Integumen, less all sums due and owing under the Note, and the assumption of certain liabilities of the Company to the value of £270,000 ($357,615). The foregoing, and any subsequent, description of the Option Agreement and the Note does not purport to be complete and is qualified in its entirety by reference to the complete text of the documents, which are filed as Exhibits 10.1 and 10.2 to the Company’s Current Report on Form 8-K filed on July 12, 2016. The ability of the Company to continue as a going concern and become a profitable entity is dependent upon the continued financial support of Mercuriali Ltd, the continuation of the promissory note and the Company’s successful efforts to conclude the APA with Integumen or to obtain and continue to obtain additional funding to reposition and re-launch its product line and generate sales and then attain profitable operations. Additional financing will be required for ongoing project management and product development costs, to complete the design work currently underway for the consumer rebranding and packaging, to manufacture prototypes for studies and promotion, to undertake marketing clinical studies, to pay on-going patent and trademark costs and to provide day to day working capital. Further funding will also be required to manage the launch process, design and implement e-Commerce platforms, undertake any additional marketing clinical studies, marketing, advertising and media support, and to provide working capital prior to market launch. Management is consequently focused on concluding the APA prior to September 8, 2016. In the event this strategic collaboration does not progress, management intends to seek alternative wider strategic collaborations and in parallel pursue alternative funding structures including debt and equity finance, asset sales, licensing and marketing partnerships. The Company would seek to appoint a broker to help it identify suitable alternative collaboration partners. . There can be no assurances, however, that management’s efforts to conclude the APA or to find alternative strategic collaborations or obtain alternative funding, licensing partners, marketing partners on terms satisfactory to the Company, or at all will, be realized or that future sales will be realized. In addition, on November 19, 2015 the Company’s President & CEO, CSO and General Counsel have agreed to amend their respective Consultancy Agreements and Employment Agreements, as amended, such that payment for services is contingent upon the Company having received cumulative Transaction Monies (as such term is defined in the relevant agreements) of at least one million United States dollars ($1,000,000) prior to April 30, 2017. Each of these agreements was amended to bring forward the start of remuneration payments with such payment being contingent on receipt of Transaction Monies (as such term is defined in the agreements), in exchange for a reduction in minimum payment obligations and minimum termination payments payable in certain circumstances. In the opinion of the Board the revised remunerations structure incentivizes management, aligns better with the Company’s future strategy and service requirements, and reduces the potential cost on a change of control which may have had a negative effect on future potential corporate transactions. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Related Party Transactions and

Related Party Transactions and Balances	3 Months Ended
	Jul. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions and Balances	NOTE 4. RELATED PARTY TRANSACTIONS AND BALANCES The details of related party balances are as follows: July 31, 2016 April 30, 2016 $ $ Unpaid remuneration 107,484 75,150 Unreimbursed expenses 457 457 Accounts payable to a related party 107,941 75,607 Unpaid remuneration 285,692 215,412 Balances owing to Mercuriali Ltd. 33,188 33,188 Accounts payable to related parties convertible into shares 318,880 248,600 Advances from a related party 96,489 96,489 Advances from a related party convertible into shares 316,575 305,540 ACCOUNTS PAYABLE TO RELATED PARTIES: Unpaid remuneration The outstanding balance of $107,484 as at July 31, 2016 represents the cash element of amounts due to related parties in connection with the consulting and employment amendment agreements effective August 1, 2015 and signed on November 19 and November 25, 2015. On February 13, 2013 Mr Donald Nicholson was appointed to the roles of President, CEO and CFO of the Company. On March 5, 2013 the Company entered into a consulting agreement with Mercuriali for the services of Mr. Nicholson as the Company’s President, CEO and CFO (the “Mercuriali Consulting Agreement”), as amended by agreements entered effective March 3, 2014, August 1, 2015 and March 21, 2016 (the “Mercuriali Amendment Agreements”). On August 14, 2008, the Company entered into an employment agreement with Samuel Asculai, our former President and Chief Executive Officer. That employment agreement had an initial term of ten (10) years and a base salary of $150,000 per annum. Pursuant to that employment agreement, Dr. Asculai received a base salary and an annual bonus equal to at least two percent (2%) of the Company’s pretax earnings, as defined, for each fiscal year. If Dr. Asculai’s employment were to be terminated without “cause”, as defined in that employment agreement, then Dr. Asculai would be entitled to receive all accrued by unpaid salary and bonus plus a payment equal to two (2) times Dr. Asculai’s highest base salary (but not less than $300,000) plus two (2) times his highest bonus. This payment would be received, at Dr. Asculai’s option, in one lump sum or in equal monthly installments over a 24 month period. On March 5, 2013, as amended March 3, 2014 Dr. Asculai, and Biostrategies (a company wholly owned by Dr. Asculai) entered a termination agreement with the Company terminating the employment agreement with Dr. Asculai as President and CEO. Pursuant to this termination agreement upon the Company substantially completing the Restructuring Plan, Biostrategies and Dr. Asculai forgive all of the unpaid fees under Dr. Asculai except for $20,031 which amount will be converted into five million three hundred twenty seven thousand four hundred and sixty (5,327,460) common shares of the Company’s stock upon the Company receiving cumulative Transaction Monies (as such term is defined in the relevant agreements) of at least one hundred and fifty thousand United States dollars ($150,000). During the year ended April 30, 2013 the Company substantially completed the Restructuring Plan. Resultantly, Dr. Asculai forgave all of the unpaid fees except for $20,031 which was transferred, together with the associated share conversion, to the balance of Mr. Puseljic. On March 5, 2013 Biostrategies entered into a new consulting agreement with the Company for the services of Dr. Asculai as the Company’s CSO (the “Asculai Consulting Agreement”), as amended by agreements entered effective March 3, 2014, August 1, 2015 and March 21, 2016 (the “Asculai Amendment Agreements”). Mr. Puseljic had a 10-year service agreement with the Company to assist in business development, contract administration and co-ordination of SEC filings with management and the Company’s SEC counsel with base fees of $150,000 per annum. At March 5, 2013 Mr. Puseljic was owed $400,625 in unpaid fees. On March 5, 2013 Mr. Puseljic entered a termination agreement with the company as amended March 3, 2014 (the “Puseljic Termination Agreement”) terminating the service agreement and pursuant to which upon the Company substantially completing the Restructuring Plan, Mr. Puseljic forgives all of the unpaid fees except for $20,031.25 which amount will be converted into five million three hundred twenty seven thousand four hundred and sixty (5,327,460) common shares of the Company’s stock upon the Company receiving cumulative Transaction Monies (as such term is defined in the relevant agreements) of at least one hundred and fifty thousand United States dollars ($150,000). On March 5, 2013 Mr. Puseljic entered into a new employment agreement with the Company (the “Puseljic Employment Agreement”), as amended by agreements entered effective March 3, 2014, August 1, 2015 and March 21, 2016 (the “Puseljic Amendment Agreements”). Under the Mercuriali Amendment Agreements, the Asculai Amendment Agreements and the Puseljic Amendment Agreements, the Corporation may be liable to pay $21,000 to each of Mr. Asculai and Mr. Puseljic and $35,500 to Mercuriali for the period August 1, 2015 to October 31, 2015 to be satisfied seventy percent (70%) in common shares of Corporation at $0.0018 and thirty percent (30%) in cash, all such payments conditional on the receipt of Transaction Monies (as such term is defined in the relevant agreements) of $1,000,000 on or prior to April 30, 2017. For the period November 1, 2015 to January 31, 2016, service fee obligations under the Mercuriali Amendment Agreement, Asculai Amendment Agreement and Puseljic Amendment Agreement each comprise a monthly retainer of seven thousand United States dollars (US$7,000) for up to fourteen (14) hours of Services per week, plus one hundred United States dollars ($100) per hour of Services provided in excess of fourteen (14) hours per week based on the level of services provided and invoiced as further set out in the agreements to be satisfied seventy percent (70%) in common shares of Corporation at $0.0018 and thirty percent (30%) in cash, all such payments conditional on the receipt of Transaction Monies (as such term is defined in the relevant agreements) of $1,000,000 on or prior to April 30, 2017. For the period from February 1, 2016, service fee obligations under the Mercuriali Amendment Agreement, Asculai Amendment Agreement and Puseljic Amendment Agreement each comprise a monthly retainer of seven thousand United States dollars (US$7,000) for up to fourteen (14) hours of Services per week, plus one hundred United States dollars ($100) per hour of Services provided in excess of fourteen (14) hours per week based on the level of services provided and invoiced as further set out in the agreements to be satisfied seventy percent (70%) in common shares of Corporation at the weighted average price of the new shares issued to non-related third parties after the March 21, 2016 (excluding shares issued under the VVG Note) and thirty percent (30%) in cash, all such payments conditional on the receipt of Transaction Monies (as such term is defined in the relevant agreements) of $1,000,000 on or prior to April 30, 2017. The foregoing information regarding the Mercuriali Consulting Agreement and the Mercurial Amendment Agreements are not intended to be complete and are qualified in their entirety by reference to the complete text of the Mercuriali Consulting Agreement, which is attached as Exhibit 99.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended January 31, 2013 and filed on March 19, 2013 and the complete text of the Mercurial Amendment Agreements which were attached as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended January 31, 2014 and filed on March 5, 2014, as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 25, 2015 and as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on March 24, 2016. The foregoing information regarding the Asculai Consulting Agreement and the Asculai Amendment Agreement are not intended to be complete and are qualified in their entirety by reference to the complete text of the Asculai Consulting Agreement, which was attached as Exhibit 99.8 to the Company’s Quarterly Report on Form 10-Q for the quarter ended January 31, 2013 and filed on March 19, 2013 and the complete text of the Asculai Amendment Agreements which were attached as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended January 31, 2014 and filed on March 5, 2014 as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on November 25, 2015 and as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on March 24, 2016. The foregoing information regarding the Puseljic Employment Agreement and the Puseljic Amendment Agreement are not intended to be complete and are qualified in their entirety by reference to the complete text of the Puseljic Employment Agreement, which was attached as Exhibit 99.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended January 31, 2013 and filed on March 19, 2013 and the complete text of the Puseljic Amendment Agreements which were attached as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended January 31, 2014 and filed on March 5, 2014, as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on November 25, 2015 and as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on March 24, 2016. On November 25, 2015, the Company and Mr. Frode Botnevik entered into a Director’s Services Agreement effective August 1, 2015 relating to Mr Botnevik’s services as a Director of the Company (the “Botnevik Services Agreement”) as amended by an agreement effective March 21, 2016 (the “Botnevik Services Amendment”). Under the Botnevik Services Agreement and the Botnevik Services Amendment, the Corporation may be liable to pay $2,500 to Mr. Botnevik for the period August 1, 2015 to October 31, 2015 to be satisfied seventy percent (70%) in common shares of Corporation $0.0018 and thirty percent (30%) in cash, all such payments conditional on the receipt of Transaction Monies (as such term is defined in the relevant agreements) of $1,000,000 on or prior to April 30, 2017. For the period November 1, 2015 to January 31, 2016, service fee obligations under the Botnevik Services Agreement and Botnevik Services Amendment comprises a quarterly retainer of two thousand five ($2,500) United States dollars for up to twenty five (25) hours of Services per quarter, plus one hundred United States dollars ($100) per hour of Services provided in excess of twenty five (25) hours per quarter based on the level of services provided and invoiced as further set out in the agreements to be satisfied seventy percent (70%) in common shares of Corporation at $0.0018 and thirty percent (30%) in cash, all such payments conditional on the receipt of Transaction Monies (as such term is defined in the relevant agreements) of $1,000,000 on or prior to April 30, 2017. For the period from February 1, 2016, service fee obligations under the Botnevik Services Agreement and Botnevik Services Amendment comprises a quarterly retainer of two thousand five ($2,500) United States dollars for up to twenty five (25) hours of Services per quarter, plus one hundred United States dollars ($100) per hour of Services provided in excess of twenty five (25) hours per quarter based on the level of services provided and invoiced as further set out in the agreements to be satisfied seventy percent (70%) in common shares of Corporation at the weighted average price of the new shares issued to non-related third parties after the March 21, 2016 (excluding shares issued under the VVG Note) and thirty percent (30%) in cash, all such payments conditional on the receipt of Transaction Monies (as such term is defined in the relevant agreements) of $1,000,000 on or prior to April 30, 2017. The foregoing information regarding the Botnevik Services Agreement and the Botnevik Services Amendment are not intended to be complete and are qualified in their entirety by reference to the complete text of the Botnevik Services Agreement which was filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on November 25, 2015 and the Botnevik Services Amendment which was filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on March 24, 2016. Unreimbursed expenses The outstanding balance of $457 represents amounts due to a related party in connection with the expenses incurred by it on behalf of the Company. The amounts due do not bear any interest and is repayable on demand. ACCOUNTS PAYABLE TO RELATED PARTIES CONVERTIBLE INTO SHARES: The outstanding balance comprise of unpaid remuneration to related parties and a balance owing to Mercuriali Ltd as detailed below: Unpaid remuneration On May 12, 2010 Biostrategies Consulting Group Inc. the holder of 27,500,000 shares of common stock of the Company transferred 9,166,666 of these shares to Drasko Puseljic. Biostrategies Consulting Group Inc. (“Biostrategies”) is 100% privately owned by Dr. Samuel Asculai, the CSO and a director of the Company. Mr. Puseljic had a 10-year service agreement with the company to assist in business development, contract administration and co-ordination of SEC filings with management and the Company’s SEC counsel. With his holdings, Mr. Puseljic has more than 5% of the outstanding equity of the Company and became a “related party”. Mr Puseljic billed the Company $150,000 during each of the previous fiscal years ended up to April 30, 2012. At April 30, 2013 Mr. Puseljic was owed $400,625 in unpaid fees On March 5, 2013 Mr. Puseljic entered a termination agreement with the company (the “Puseljic Termination Agreement”) pursuant to which upon the Company substantially completing the Restructuring Plan, Mr. Puseljic forgives all of the unpaid fees except for $20,031 which amount will be converted into five million three hundred twenty seven thousand four hundred and sixty (5,327,460) common shares of the Company’s stock upon the Company receiving cumulative Transaction Monies (as such term is defined in the relevant agreements) of at least one hundred and fifty thousand United States dollars ($150,000). During the year ended April 30, 2013 the Company substantially completed the Restructuring Plan. Resultantly, Mr. Puseljic forgave all of the unpaid fees except for $20,031. Further, the unpaid fee balance of Dr. Asculai of $20,031 described in the following paragraph, together with the associated share conversion, was also transferred to Mr. Puseljic’s balance. Therefore, Mr. Puseljic’s balance of $40,062 is included in total unpaid remuneration balance as at January 31, 2016, which amount will be converted into ten million six hundred fifty four thousand nine hundred and twenty (10,654,920) common shares of the Company’s stock upon the Company receiving cumulative Transaction Monies (as such term is defined in the relevant agreements) of at least one hundred and fifty thousand United States dollars ($150,000). The Company incurred monthly consulting fee expenses of $12,500 to either Biostrategies or Samuel Asculai, the Company’s then CEO and Director. The Company recorded $150,000 as an expense during each of the previous fiscal years ended up to April 30, 2012. At April 30, 2013, $400,625 of these expenses were unpaid On March 5, 2013 Biostrategies and Dr. Asculai entered a termination agreement with the Company (the “Asculai Termination Agreement”) pursuant to which upon the Company substantially completing the Restructuring Plan, Biostrategies and Dr. Asculai forgive all of the unpaid fees except for $20,031 which amount will be converted into five million three hundred twenty seven thousand four hundred and sixty (5,327,460) common shares of the Company’s stock upon the Company receiving cumulative Transaction Monies (as such term is defined in the relevant agreements) of at least one hundred and fifty thousand United States dollars ($150,000). During the previous year ended April 30, 2013 the Company substantially completed the Restructuring Plan. Resultantly, Dr. Asculai forgave all of the unpaid fees except for $20,031 which was transferred, together with the associated share conversion, to the balance of Mr. Puseljic, which amounted to $40,062 at July 31, 2016. In addition, the outstanding balance as at July 31, 2016 includes $245,630 representing amounts due to related parties, which may be payable in shares, under the consulting and employment amendment agreements effective August 1, 2015 and signed on November 19 and November 25, 2015 as summarised above under Accounts Payable to Related Parties; Unpaid remuneration. Balance owing to Mercuriali Ltd. On July 12, 2010 the Company entered into a Termination and Settlement Agreement (the “Settlement Agreement”) with Mercuriali Ltd. (“Mercuriali”), a company controlled by Donald Nicholson, a then director of the Company and now a director and the Company’s President, Chief Executive Officer and Chief Financial Officer. The Settlement Agreement terminated a Letter of Intent between the Company and Mercuriali regarding a proposed merger between the Company and Mercuriali as part of a larger transaction involving the reverse merger of the Company into a company listed on AIM, a sub-market of the London Stock Exchange. Neither the merger between Mercuriali and the Company, nor the reverse merger of the Company and the AIM listed company took place. Under the Settlement Agreement, the Company agreed to pay Mercuriali expenses incurred pursuant to the Letter of Intent of GBP 22,082 payable at a rate of 5% of gross funds raised by the Company. After receiving proceeds from financing the Company will pay 5% of the gross proceeds to Mercuriali until the obligation has been paid. Other than the items provided for in the Termination Agreement, the Company and Mercuriali released each other from all claims relating to the Letter of Intent. Through the previous year ended April 30, 2012 the Company has raised $60,000 of funds from the issuance of Common Stock, 5% of this or $3,000 should have been paid to satisfy this obligation; however, only $1,500 was paid during the previous fiscal years ended April 30, 2013. As of April 30, 2016 the balance owed to Mercuriali is $33,188. The balance is secured by the assets of the Company. Upon the Company restructuring at least seventy five percent (75%) of its outstanding debt substantially in accordance with the Restructuring Plan and upon the Company receiving additional Transaction Monies (as such term is defined in the relevant agreements) of at least $250,000, Mercuriali shall convert the total amounts owed to it under the Loan Agreement into common shares of the Company at a conversion price of $0.00376 per share. The balance is secured by all of the assets of the Company and does not bear interest. ADVANCES FROM A RELATED PARTY As of July 31, 2016, the Company owes $96,489 (April 30, 2016 - $96,489) in respect of advances from Dr. Asculai, its former CEO and current Chief Scientific Officer and Chairman of the Board, pursuant to the Loan Agreement. This balance is to be paid in quarterly installments after the Company has cumulatively raised one million United States dollars. The Advances are secured by all of the assets of the Company and do not bear interest. ADVANCES FROM A RELATED PARTY CONVERTIBLE INTO SHARES These advances are from Mercuriali Ltd. pursuant to the Loan Agreement . As at July 31, 2016, Mercuriali has advanced a total of $316,575 (April 30, 2016 - $305,540) to the Company pursuant to the Loan Agreement. Mercuriali shall convert $188,357 of the amounts owed to it under the Loan Agreement into common shares of the Company at a conversion price of $0.00376 per share and $128,218 of the amounts owed to it under the Loan Agreement into common shares of the Company at a conversion price of $0.0018 per share upon the Company receiving additional Transaction Monies (as such term is defined in the relevant agreements) of at least $250,000. Effective September 29, 2015, the Company entered into a Loan Agreement (Amendment 3) with Mercuriali Ltd. and Samuel Asculai. This agreement amended loan agreements between the parties dated March 4, 2013 and March 3, 2014 and provided for a loan of US$45,000 from Mercuriali Ltd. and Samuel Asculai in the event no additional third party monies were received by the Company. Upon certain conditions set out in the Loan Agreement (Amendment 3), the amounts so loaned by Mercuriali Ltd. and Samuel Asculai will be convertible into common shares of the Company at the lower of $0.0047753 or the conversion price at which the promissory note the Company issued to Vis Vires converts. See Note 5; Convertible Promissory Note. The price of $0.0047753 was set at 58% of the average of the lowest three closing trading prices for the common stock during the ten trading days prior to September 25, 2015, on the calculation basis described in the Vis Vires promissory note. Effective January 22, 2016, the Company entered into a Loan Agreement (Amendment 4) with Mercuriali Ltd. and Samuel Asculai. This agreement amends loan agreements between the parties dated March 4, 2013, March 3, 2014 and September 29, 2015 and provides for an increase in the loan amounts by Mercuriali Ltd. and Samuel Asculai in the event no additional third party monies are received by the Company from US$45,000 to US$90,000. Upon certain conditions set out in the Loan Agreement (Amendment 4), the amounts so loaned by Mercuriali Ltd. and Samuel Asculai will be convertible into common shares of the Company at the lower of $0.0047753 or the conversion price at which the promissory note the Company issued to Vis Vires converts. Effective March 21, 2016, the Company entered into a Loan Agreement (Amendment 5) with Mercuriali Ltd. and Samuel Asculai This agreement amends loan agreements between the parties dated March 4, 2013, March 3, 2014, September 29, 2015 and January 22, 2016 and provides for an increase in the loan amounts by Mercuriali Ltd. and Samuel Asculai in the event no additional third party monies are received by the Company from US$90,000 to US$150,000. Upon certain conditions set out in the Loan Agreement (Amendment 5), the amounts so loaned by Mercuriali Ltd. and Samuel Asculai will be convertible into common shares of the Company at $0.0018, based on the conversion price at which the promissory note the Company issued to Vis Vires converted or was repaid. The advances from Mercuriali Ltd and Samuel Asculai are secured on all of the assets of the Company and do not bear interest.

Secured Promissory Note

Secured Promissory Note	3 Months Ended
	Jul. 31, 2016
Debt Disclosure [Abstract]
Secured Promissory Note	NOTE 5. SECURED PROMISSORY NOTE On July 7, 2016, the Company and Integumen Limited (formerly Biosurface Limited) entered into a non-binding term sheet in respect of a strategic collaboration and an option agreement (the “Option Agreement”). The Company also issued to Integumen a secured promissory note in the amount of $100,000 (the “Note”). The Option Agreement grants Biosurface an option to acquire substantially all of the Company’s assets under a plan of reorganization (the “Option”). The consideration payable upon exercise of the Option is a sum equal to £3,030,000 ($4,013,293) comprised of £2,760,000 ($3,655,620) in shares of Integumen, less all sums due and owing under the Note, and the assumption of certain liabilities of the Company to the value of £270,000 ($357,615). The Option expires on September 8, 2016 and may only be exercised after the Note has been entered into and Integumen has transferred sum equal to US$100,000 in accordance with the terms of the Note. The Company received the $100,000 on July 12, 2016. Under the Note, Integumen agrees to loan the Company US$100,000 conditional upon the Company entering into the Option Agreement and entering into good faith negotiations with a view to entering into an asset purchase agreement (the “APA”). All unpaid principal is due and payable on or following the six month anniversary of the Note (the “Maturity Date”), the completion of the APA or upon an event of default as defined in the Note. The Note shall not accrue interest prior to the Maturity Date, but interest shall accrue at 5% per annum following the Maturity Date or following certain Events of Default as set out in the Note. The Note is secured by a first fixed and floating charge over the Company’s intellectual property. US dollar amounts are provided for the convenience of readers only and are based on the amounts in pounds sterling translated into US dollars at the closing sterling/dollar interbank rate on July 31, 2016.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Jul. 31, 2016
Equity [Abstract]
Stockholders' Deficit	NOTE 6. STOCKHOLDERS’ DEFICIT COMMON SHARES - AUTHORIZED As at July 31, 2016, the Company had 600,000,000 common shares authorized (April 30, 2016: 300,000,000 common shares). The common shares have a $0.001 par value. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they chose to do so, elect all of the directors of the Company. COMMON SHARES - ISSUED AND OUTSTANDING On July 29, 2016, the Company issued 1,937,500 shares of common stock to Snowbell Management Limited in connection with the services provided by them to develop the Visible Youth™ consumer skin care brand for its relaunch. Management had agreed on the share price of $0.00702 per common stock on July 15, 2016. These shares were then valued at market price of $0.0075 per common stock and accordingly $14,531 has been recorded, of which $6,585 was included in legal and professional fees and $7,947 in prepaid expenses, for the three months ended July 31, 2016. As at July 31, 2016 there were 115,889,205 shares of common stock issued an outstanding (April 30, 2016: 113,951,705 common shares).

Interest Expense

Interest Expense	3 Months Ended
	Jul. 31, 2016
Other Income and Expenses [Abstract]
Interest Expense	NOTE 7. INTEREST EXPENSE July 31, 2016 July 31, 2015 $ $ Beneficial conversion feature on advances from a related party 7,821 2,183 Accretion expense on convertible promissory note — 4,555 Interest accrued on convertible promissory note — 405 Total interest expense 7,821 7,143 Interest expense represents beneficial conversion feature of the advances from a related party convertible into shares, expensed immediately due to short term conversion terms of these advances. Accretion expense and interest accrued for the period ended July 31, 2015 related to a convertible promissory note issued and settled during the previous year ended April 30, 2016.

Business Acquisition

Business Acquisition	3 Months Ended
	Jul. 31, 2016
Business Combinations [Abstract]
Business Acquisition	NOTE 8. BUSINESS ACQUISITION ASC Topic 805, “Business Combinations” requires that all business combinations be accounted for using the acquisition method and that certain identifiable intangible assets acquired in a business combination be recognized as assets apart from goodwill. ASC Topic 350, “Intangibles-Goodwill and Other” (“ASC 350”) requires goodwill and other identifiable intangible assets with indefinite useful lives not be amortized, such as trade names, but instead tested at least annually for impairment (which the Company tests each year end, absent any impairment indicators) and be written down if impaired. ASC 350 requires that goodwill be allocated to its respective reporting unit and that identifiable intangible assets with finite lives be amortized over their useful lives. Pursuant to Share Purchase Agreement (the “Agreement”) dated October 31, 2015, among the Company, Mercuriali Ltd. a Corporation incorporated under the laws of United Kingdom (100% owner of issued and outstanding share of Visible Youth Ltd.) and Donald Nicholson, the Company acquired 100% of the issued and outstanding shares of Visible Youth Ltd. for a consideration of $2,500. As a result of this transaction, Visible Youth Ltd. became a wholly owned subsidiary of the Company. The Company intends to use Visible Youth Limited for the marketing of its products in the European Union. This acquisition was accounted for using the acquisition method of accounting. Visible Youth Ltd. did not have any assets or liabilities as at October 31, 2015. Goodwill of $1 represents the excess of cost over fair value of net assets acquired, less impairment. The Company test for impairment of goodwill at the reporting unit level. In assessing whether goodwill is impaired, the Company utilize the two-step process as prescribed by ASC 350. The first step of this test compares the fair value of the reporting unit, determined based upon discounted estimated future cash flows, to the carrying amount, including goodwill. If the fair value exceeds the carrying amount, no further work is required and no impairment loss is recognized. If the carrying amount of the reporting unit exceeds the fair value, the goodwill of the reporting unit is potentially impaired and step two of the goodwill impairment test would need to be performed to measure the amount of an impairment loss, if any. In the second step, the impairment is computed by comparing the implied fair value of the reporting unit’s goodwill with the carrying amount of the goodwill. If the carrying amount of the reporting unit’s goodwill is greater than the implied fair value of its goodwill, an impairment loss in the amount of the excess is recognized and charged to statement of operations. Management decided to immediately impair goodwill amounting to $2,499 and brought it at $1 as Visible Youth Ltd. was inactive as at July 31, 2016.

Subsequent Events

Subsequent Events	3 Months Ended
	Jul. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	NOTE 9. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events up to September 1, 2016, the date the condensed financial statements were issued, pursuant to the requirements of ASC Topic 855 and has determined the following material subsequent event to report. On August 12, 2016, the Company and Integumen Limited (formerly Biosurface) entered into an agreement amending the Option Agreement entered into by the parties on July 7, 2016 as amended July 29, 2016 (refer Note 5). The Option Amendment Agreement extends the expiration date of the option in the Option Agreement from August 12, 2016 to August 24, 2016. All other terms of the Option Agreement remained unchanged. On August 24, 2016, the Company and Integumen Limited (formerly Biosurface) entered into an agreement amending the Option Agreement entered into by the parties on July 7, 2016 as amended July 29, 2016 and August 12, 2016 (refer Note 5). The Option Amendment Agreement extends the expiration date of the option in the Option Agreement from August 24, 2016 to September 1, 2016. All other terms of the Option Agreement remain unchanged. On September 1, 2016, the Company and Integumen Limited (formerly Biosurface) entered into an agreement amending the Option Agreement entered into by the parties on July 7, 2016 as amended July 29, 2016, August 12, 2016 and August 24, 2016 (refer Note 5). The Option Amendment Agreement extends the expiration date of the option in the Option Agreement from September 1, 2016 to September 8, 2016. All other terms of the Option Agreement remain unchanged.

Related Party Transactions an15

Related Party Transactions and Balances (Tables)	3 Months Ended
	Jul. 31, 2016
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The details of related party balances are as follows: July 31, 2016 April 30, 2016 $ $ Unpaid remuneration 107,484 75,150 Unreimbursed expenses 457 457 Accounts payable to a related party 107,941 75,607 Unpaid remuneration 285,692 215,412 Balances owing to Mercuriali Ltd. 33,188 33,188 Accounts payable to related parties convertible into shares 318,880 248,600 Advances from a related party 96,489 96,489 Advances from a related party convertible into shares 316,575 305,540

Interest Expense (Tables)

Interest Expense (Tables)	3 Months Ended
	Jul. 31, 2016
Other Income and Expenses [Abstract]
Summary of Interest Expense	July 31, 2016 July 31, 2015 $ $ Beneficial conversion feature on advances from a related party 7,821 2,183 Accretion expense on convertible promissory note — 4,555 Interest accrued on convertible promissory note — 405 Total interest expense 7,821 7,143

Going Concern (Details Narrativ

Going Concern (Details Narrative)

Jul. 12, 2016USD ($)

Jul. 07, 2016USD ($)

Jul. 07, 2016GBP (£)

Mar. 23, 2016USD ($)

Mar. 21, 2016USD ($)

Dec. 28, 2015USD ($)$ / sharesshares

Nov. 19, 2015USD ($)

Jul. 31, 2016USD ($)

Apr. 30, 2016USD ($)

Jan. 31, 2016$ / shares

Jan. 22, 2016USD ($)

Jun. 19, 2015USD ($)

Working capital deficit

$ 1,150,560

Accumulated deficit

$ 3,267,443

$ 3,089,331

Debt conversion price per share | $ / shares

$ 0.0018

Repayment of debt

$ 33,500

President & CEO, CSO and General Counsel [Member] | April 30, 2017 [Member]

Payment for services

$ 1,000,000

Mercuriali Ltd [Member]

Advance from related party

$ 90,000

Integumen Limited [Member] | Option Agreement [Member]

Proceeds from loans

$ 100,000

Secured promissory note

$ 100,000

Assumption of certain liabilities

$ 357,615

Percentage of accrued interest per annum

5.00%

Integumen Limited [Member] | Option Agreement [Member] | GBP [Member]

Assumption of certain liabilities | £

£ 270,000

Integumen Limited [Member] | Option Agreement [Member] | Minimum [Member]

Exercise of option

$ 4,013,293

Integumen Limited [Member] | Option Agreement [Member] | Minimum [Member] | GBP [Member]

Exercise of option | £

3,030,000

Integumen Limited [Member] | Option Agreement [Member] | Maximum [Member]

Exercise of option

$ 3,655,620

Integumen Limited [Member] | Option Agreement [Member] | Maximum [Member] | GBP [Member]

Exercise of option | £

£ 2,760,000

Vis Vires Group Inc [Member]

Value of convertible promissory note issued

$ 43,000

Conversion of promissory note into shares, value

$ 12,000

Debt conversion price per share | $ / shares

$ 0.0017

Conversion of promissory note shares | shares

7,058,824

Mercuriali [Member] | Loan Agreement (Amendment 5) [Member] | Minimum [Member]

Proceeds from loans

$ 90,000

Mercuriali [Member] | Loan Agreement (Amendment 5) [Member] | Maximum [Member]

Proceeds from loans

$ 150,000

Related Party Transactions an18

Related Party Transactions and Balances (Details Narrative)	Jul. 31, 2016USD ($)$ / shares	Mar. 21, 2016USD ($)$ / shares	Oct. 31, 2015USD ($)$ / sharesshares	Sep. 29, 2015USD ($)$ / shares	Mar. 03, 2014USD ($)shares	Apr. 30, 2013USD ($)shares	Mar. 05, 2013USD ($)shares	Apr. 30, 2012USD ($)	May 12, 2010USD ($)shares	Aug. 14, 2008USD ($)	Jan. 31, 2016USD ($)$ / shares	Oct. 31, 2015USD ($)$ / shares	Apr. 30, 2013USD ($)	Apr. 30, 2012USD ($)	Apr. 30, 2016USD ($)	Feb. 02, 2016USD ($)	Jan. 22, 2016USD ($)$ / shares	Apr. 30, 2015USD ($)	Jul. 12, 2010GBP (£)
Outstanding balance	$ 107,484
Pay total aggregate sum												$ 21,000
Percentage of satisfied common shares of corporation		70.00%									70.00%	70.00%
Conversion price per share | $ / shares											$ 0.0018
Percentage of note converts in cash		30.00%									30.00%	30.00%
Unreimbursed expenses	457														$ 457
Due to related party with expenses incurred by behalf of company	245,630
Expenses recorded during the period													$ 400,625	$ 150,000
Percentage of accounts payable from gross funds																			5.00%
Fund raised from issuance of common stock								$ 60,000
Amount paid to satisfy the obligation								$ 3,000					1,500
Additional financing arrangement	1,991,963
GBP [Member]
Letter of intent | £																			£ 22,082
Mercuriali Ltd [Member]
Pay total aggregate sum												$ 35,500
Biostrategies Consulting Group Inc [Member]
Number of shares outstanding | shares									27,500,000
Drasko Puseljic [Member]
Number of shares transferred in transaction | shares									9,166,666
Biostrategies Or Samuel Asculai [Member]
Consulting fee expenses											$ 12,500
Mercuriali [Member]
Due to related parties	$ 316,575					$ 33,188							33,188		305,540
Common stock conversion price per share | $ / shares	$ 0.00376
Conversion of stock value converted	$ 188,357
Prior to April 30, 2017 [Member]
Minimum cumulative financings arrangement			$ 1,000,000								1,000,000	$ 1,000,000			1,000,000	$ 1,000,000
Upto Fourteen Hours Of Services Per Week [Member]
Service fee obligations											7,000					7,000
Excess Of Fourteen Hours Of Services Per Week [Member]
Service fee obligations											100					$ 100
Upto Twenty Five Hours Of Services Per Quarter [Member] | Botnevik Services Agreements [Member]
Service fee obligations											2,500
Excess Of Twenty Five Hours Of Services Per Quarter [Member] | Botnevik Services Agreements [Member]
Service fee obligations											$ 100
Mr.Puseljic [Member]
Forgiveness of unpaid fees							$ 20,031
Conversion of promissory note shares | shares							5,327,460
Conversion of promissory note into shares, value							$ 150,000
Unpaid fees							400,625
Ownership percentage									5.00%
Number of service agreement years with company									10 years
Outstanding billed amount by related party									$ 150,000
Amount owed to unpaid fees						400,625							400,625
Value of unpaid fee converted into common shares						$ 20,031							20,031
Unpaid fee converted into number of shares | shares			10,654,920			5,327,460
Minimum amount of cumulative fundraisings						$ 150,000							150,000		150,000
Unpaid remuneration															$ 40,062
Mr.Asculai Mr.Puseljic Mercuriali [Membe]
Percentage of satisfied common shares of corporation												70.00%
Conversion price per share | $ / shares			$ 0.0018									$ 0.0018
Percentage of note converts in cash												30.00%
Mr. Botnevik [Member]
Percentage of satisfied common shares of corporation												70.00%
Conversion price per share | $ / shares			$ 0.0018									$ 0.0018
Percentage of note converts in cash												30.00%
Dr. Samuel Asculai [Member] | Biostrategies Consulting Group Inc [Member]
Ownership percentage									100.00%
Dr. Asculai [Member]
Due to related parties	96,489																	$ 96,489
Value of unpaid fee converted into common shares						$ 20,031							20,031
Unpaid fee converted into number of shares | shares						5,327,460
Minimum amount of cumulative fundraisings						$ 150,000							150,000
Unpaid remuneration						40,062							40,062
Employment Agreement with Samuel Asculai [Member]
Debt term										10 years
Base salary per annum										$ 150,000
Percentage of base salary and annual bonus equal to at least										2.00%
Base salary description										times Dr. Asculai’s highest base salary (but not less than $300,000) plus two (2) times his highest bonus. This payment would be received, at Dr. Asculai’s option, in one lump sum or in equal monthly installments over a 24 month period.
Dr.Asculai and Biostrategies Termination Agreement [Member]
Forgiveness of unpaid fees					$ 20,031
Conversion of promissory note shares | shares					5,327,460
Conversion of promissory note into shares, value					$ 150,000
Unpaid fees						$ 20,031							$ 20,031
Asculai Consulting Service Agreement [Member]
Base salary per annum							$ 150,000
Service agreement term							10 years
Loan Agreement [Member] | Mercuriali [Member]
Due to related parties	128,218
Additional financing arrangement	$ 250,000
Common stock conversion price per share | $ / shares	$ 0.0018
Loan Agreement [Member] | Mercuriali Ltd. and Samuel Asculai [Member]
Conversion price per share | $ / shares		$ 0.0018
Percentage of average lowest three closing trading prices				58.00%
Due to related parties				$ 45,000													$ 90,000
Common stock conversion price per share | $ / shares				$ 0.0047753													$ 0.0047753
Loan Agreement [Member] | Amendment 4 [Member] | Mercuriali Ltd. and Samuel Asculai [Member] | Minimum [Member]
Proceeds from loans		$ 45,000
Loan Agreement [Member] | Amendment 4 [Member] | Mercuriali Ltd. and Samuel Asculai [Member] | Maximum [Member]
Proceeds from loans		90,000
Loan Agreement [Member] | Amendment 5 [Member] | Mercuriali Ltd. and Samuel Asculai [Member] | Minimum [Member]
Proceeds from loans		90,000
Loan Agreement [Member] | Amendment 5 [Member] | Mercuriali Ltd. and Samuel Asculai [Member] | Maximum [Member]
Proceeds from loans		$ 150,000

Related Party Transactions An19

Related Party Transactions And Balances - Schedule of Related Party Transactions (Details) - USD ($)	Jul. 31, 2016	Apr. 30, 2016
Related Party Transactions [Abstract]
Unpaid remuneration	$ 107,484	$ 75,150
Unreimbursed expenses	457	457
Accounts payable to a related party	107,941	75,607
Unpaid remuneration	285,692	215,412
Balances owing to Mercuriali Ltd.	33,188	33,188
Accounts payable to related parties convertible into shares	318,880	248,600
Advances from a related party	96,489	96,489
Advances from a related party convertible into shares	$ 316,575	$ 305,540

Secured promissory note (Detail

Secured promissory note (Details Narrative) - Option Agreement [Member]	Jul. 31, 2016USD ($)	Jul. 12, 2016USD ($)	Jul. 07, 2016USD ($)	Jul. 07, 2016GBP (£)
Biosurface Limited [Member]
Secured promissory note			$ 100,000
Assumption of certain liabilities			357,615
Number of shares received by option	$ 100,000
Loans payable			$ 100,000
Percentage of accrued interest rate	5.00%
Debt instrument maturity date			Sep. 8, 2016	Sep. 8, 2016
Biosurface Limited [Member] | GBP [Member]
Assumption of certain liabilities			$ 270,000
Biosurface Limited [Member] | Minimum [Member]
Exercise of option			4,013,293
Biosurface Limited [Member] | Minimum [Member] | GBP [Member]
Exercise of option			3,030,000
Biosurface Limited [Member] | Maximum [Member]
Exercise of option			3,655,620
Biosurface Limited [Member] | Maximum [Member] | GBP [Member]
Exercise of option			2,760,000
Integumen Limited [Member]
Secured promissory note			100,000
Assumption of certain liabilities			357,615
Number of shares received by option		$ 100,000
Integumen Limited [Member] | GBP [Member]
Assumption of certain liabilities | £				£ 270,000
Integumen Limited [Member] | Minimum [Member]
Exercise of option			4,013,293
Integumen Limited [Member] | Minimum [Member] | GBP [Member]
Exercise of option | £				3,030,000
Integumen Limited [Member] | Maximum [Member]
Exercise of option			$ 3,655,620
Integumen Limited [Member] | Maximum [Member] | GBP [Member]
Exercise of option | £				£ 2,760,000

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	3 Months Ended
	Jul. 31, 2016	Jul. 29, 2016	Jul. 15, 2016	Apr. 30, 2016
Common Stock, Shares Authorized	600,000,000			300,000,000
Common Stock, Par Value	$ 0.001			$ 0.001
Minimum percentage of common stock held for voting rights	50.00%
Common Stock, Shares Issued	115,889,205			113,951,705
Common Stock, Shares Outstanding	115,889,205			113,951,705
Equity issuance price per share	$ 0.0075
Legal and professional fees	$ 6,585
Prepaid Expense	7,947
Common Stock, Value, Issued	115,889			$ 113,951
Snowbell Management Limited [Member]
Common Stock, Shares Issued		1,937,500
Equity issuance price per share			$ 0.00702
Common Stock, Value, Issued	$ 14,531

Interest Expense - Summary of I

Interest Expense - Summary of Interest Expense (Details) - USD ($)	3 Months Ended
	Jul. 31, 2016	Jul. 31, 2015
Interest accrued on convertible promissory note	$ 7,821	$ 7,143
Interest Expense [Member]
Beneficial conversion feature on advances from a related party	7,821	2,183
Accretion expense on convertible promissory note		4,555
Interest accrued on convertible promissory note		405
Total interest expense	$ 7,821	$ 7,143

Business Acquisition (Details N

Business Acquisition (Details Narrative) - USD ($)	3 Months Ended
	Jul. 31, 2016	Oct. 31, 2015	Apr. 30, 2016
Business acquisition consideration transferred		$ 2,500
Goodwill less impairment of assets	$ 1		$ 1
Goodwill impairment	$ 2,499
Visible Youth Ltd [Member]
Percentage of ownership in subsidiary	100.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Sep. 01, 2016	Aug. 24, 2016	Aug. 12, 2016
Subsequent Event [Member] | Option Amendment Agreement [Member] | Integumen Limited [Member]
Option agreement extends expiration date	September 1, 2016 to September 8, 2016	August 24, 2016 to September 1, 2016	August 12, 2016 to August 24, 2016